Based on FFPE samples, the positive detection rates of the SHOX2 and RASSF1A panels in SCLC, SCC, and adenocarcinomas were 100%, 96.1%, and 82.9%, respectively. This evidence concerns the gene SHOX2 and adenocarcinoma.